---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-281574"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2023-11-21T23:59:59+00:00"
generated_at: "2026-06-07T22:28:41.366106+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharma EVP R&D Doug Williamson to depart; search for replacement underway

## Summary
- Doug Williamson, MD, EVP Head of R&D, leaving Acadia to pursue other opportunities.
- Williamson joined Acadia in January 2023 and will remain during a transitional period.
- Company has initiated a search for a replacement EVP of Research and Development.
- No financial impact or guidance changes disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-23-281574
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2023-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/0001193125-23-281574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/d586090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-281574
- JSON: https://secwatch.observer/filing/0001193125-23-281574.json
- Plain text: https://secwatch.observer/filing/0001193125-23-281574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.